Protocol No. CL010_168: A Randomized, Double-Blind, Plac

Project: Research project

Project Details

Description

Protocol No. CL010_168: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)- Associated Vasculitis Treated Concomitantly with
StatusActive
Effective start/end date11/1/1712/31/22

Funding

  • ChemoCentryx, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.